Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2003
03/20/2003WO2003022209A2 Crystalline forms of valacyclovir hydrochloride
03/20/2003WO2003022192A1 Eustachian tube stent
03/20/2003WO2003022052A1 Method for expression of small rna molecules within a cell
03/20/2003WO2003000848A3 Liver engrafting cells, assays, and uses thereof
03/20/2003WO2003000280A3 Abin-mediated hepatitis protection
03/20/2003WO2002101412A3 Spray freeze-dried compositions
03/20/2003WO2002100845A8 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/20/2003WO2002098363A3 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
03/20/2003WO2002096366A3 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
03/20/2003WO2002096354A3 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002092131A3 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
03/20/2003WO2002087424A3 Treatment and diagnosis of macrophage mediated disease
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002074910A3 Selective anti-viral nucleoside chain terminators
03/20/2003WO2002074758A3 Novel amines as histamine-3 receptor ligands and their therapeutic applications
03/20/2003WO2002067951A3 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
03/20/2003WO2002060452A3 Use of carbohydrates for eliminating intestinal infections in animals
03/20/2003WO2002053733A3 Regulation of human b7-h2 protein
03/20/2003WO2002053728A3 Gene disruption methodologies for drug target discovery
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003WO2002046189A3 Aryl ether substituted imidazoquinolines
03/20/2003WO2002040529A3 Diastereomeric peptides and pharmaceutical compositions comprising them
03/20/2003WO2002028427A3 Pharmaceutical composition for immunisation against aids
03/20/2003WO2002028408A3 Compositions and methods for the transport of biologically active agents across cellular barriers
03/20/2003WO2002026726A9 Antiviral compositions and methods of use
03/20/2003WO2002024897A9 Conditionally replicating viral vectors and their use
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002018445A9 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
03/20/2003WO2002012245B1 Azabicyclic derivatives and their therapeutic use
03/20/2003WO2001073104A9 Beta-glucans from filamentous fungi
03/20/2003US20030055286 Il-8 receptor antagonists
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055110 Retinoid compounds suited for antibacterial applications
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055071 For therapy, prophylaxis or delaying the onset of AIDS and infection by HIV
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055067 For therapy and prophylaxis of fungal infections
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055053 For therapy of bacterial and protozoal infections in mammals
03/20/2003US20030055048 Compositions and methods for treating or preventing convulsions or seizures
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055034 Preparing a concentrated inhalable aztreonam formulation comprising aztreonam dissolved in an aerosolable solution; delivering aztreonam dry powder or the aerosolable solution to the lung endobronchial space of airways of a patient
03/20/2003US20030055025 For therapy of bacterial infections and neoplasms,
03/20/2003US20030055013 Administering ribavirin for a time sufficient to lower viral-RNA in association with a therapeutically effective amount of an antioxidant therapy comprising S-adenosyl methionine to ameliorate ribavirin-related hemolysis
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054981 Parenteral formulation of an echinocandin compound, the micelle-forming surfactant, and a nontoxic, aqueous solvent, in given weight ratio of surfactant to echinocandin; treating fungal infections
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054554 Albumin derivatives with therapeutic functions
03/20/2003US20030054525 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R / (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
03/20/2003US20030054493 Identification of neutralizing epitopes of toxin A and toxin B for the treatment of C. difficile disease
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054398 Isolated human aminotransferase proteins, nucleic acid molecules encoding aminotransferase proteins and uses thereof
03/20/2003US20030054382 Infection of eukaryotic cells with viruses in vitro
03/20/2003US20030054341 Viral nucleotide sequences for use in diagnosis, prevention and treatment of viral diseases
03/20/2003US20030054047 Administering plant extract; solvent extraction
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030054042 Stabilization of chemical compounds using nanoparticulate formulations
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054016 Methods and vaccines for providing in OVO protection against turkey rhinotracheitis
03/20/2003US20030054013 Tuberculosis therapy; anticancer agents
03/20/2003US20030054010 Molecular antigen array
03/20/2003US20030054008 Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis
03/20/2003US20030053990 Virus vectors and methods of making and administering the same
03/20/2003US20030053987 Synthetic hepatitis c genes
03/20/2003US20030053986 Method of treating hepatitis C infection
03/20/2003US20030053984 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
03/20/2003CA2461692A1 Use of a protein of the crmp family for treating diseases related to the immune system
03/20/2003CA2460509A1 Synthetic hcv envelope proteins and their use for vaccination
03/20/2003CA2460331A1 Use of a protein for the production of a medicament for stimulating the innate non-specific immune system
03/20/2003CA2460269A1 Alphavirus replicon vector systems
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459769A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
03/20/2003CA2459766A1 Oxazolidinone and/or isoxazoline as antibacterial agents
03/20/2003CA2459760A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459445A1 Benzothiepine ileal bile acid transport inhibitors
03/20/2003CA2459426A1 Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
03/20/2003CA2459307A1 Compositions comprising mixtures of therapeutic proteins and methods of producing the same
03/20/2003CA2459168A1 Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
03/20/2003CA2458302A1 New assay for inhibitors of translocases
03/20/2003CA2458029A1 Methods of treating cytokine mediated diseases
03/20/2003CA2457835A1 Crystalline forms of valacyclovir hydrochloride
03/20/2003CA2457441A1 Infectious and attenuated bovine viral diarrhea virus clone; methods for their production and use
03/20/2003CA2457282A1 Method for expression of small antiviral rna molecules within a cell
03/20/2003CA2456561A1 Multiplication of viruses in a cell culture
03/20/2003CA2452194A1 Sustained release pharmaceutical compositions comprising a silicone support material
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003CA2451254A1 Novel proteins and nucleic acids encoding same
03/19/2003WO2002023992A1 Disinfectant agent
03/19/2003EP1293562A1 Fungal glyoxal oxidases
03/19/2003EP1293514A1 Multimeric single chain tandem Fv-antibodies
03/19/2003EP1293214A2 LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation
03/19/2003EP1293207A1 Use of ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating aids
03/19/2003EP1293201A2 Use of aminoadamantane compounds as immunoregulators
03/19/2003EP1293131A1 Throat care agents
1 ... 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 ... 1798